Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression

被引：8

作者：

Kim, Hyun Jung ^{[1
,2
]}

Lee, Sukmook ^{[3
]}

Oh, Yong-Seok ^{[4
]}

Chang, Ha Kyun ^{[5
]}

Kim, Young Sang ^{[6
]}

Hong, Sung Hee ^{[6
,7
]}

Kim, Jung Yong ^{[6
]}

Park, Young-Whan ^{[6
]}

Lee, Song-Jae ^{[8
]}

Song, Seong-Won ^{[8
]}

Kim, Jung Ju ^{[8
]}

Heo, Kyun ^{[1
]}

机构：

[1] Natl Canc Ctr, Res Inst, Goyang Si, South Korea

[2] Ewha Womans Univ, Dept Bioinspired Sci, Seoul, South Korea

[3] Kookmin Univ, Dept Appl Chem, Seoul, South Korea

[4] Daegu Gyeongbuk Inst Sci & Technol, Dept Brain Cognit Sci, Daegu, South Korea

[5] Res Inst & Hosp, Ctr Uterine Canc, Natl Canc Ctr, Goyang Si, South Korea

[6] Natl Canc Ctr, Natl OncoVenture, Goyang Si, South Korea

[7] Hanmi Pharm Co Ltd, Clin Res Team, Seoul, South Korea

[8] Yooyoung Pharmaceut Co Ltd, Yooyoung Cent Res Inst, Seoul, South Korea

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

HGF; humanized monoclonal antibody; ovarian cancer; metastasis; YYB-101; PEGYLATED LIPOSOMAL DOXORUBICIN; SMALL-MOLECULE INHIBITOR; C-MET; PHASE-II; EUROPEAN-ORGANIZATION; GYNECOLOGIC-ONCOLOGY; SURFACE EPITHELIUM; BRCA2; MUTATIONS; STAGE OVARIAN; FACTOR HGF;

D O I：

10.3389/fonc.2019.00571

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current chemotherapy regimens have certain limitations in improving the survival rates of patients with advanced ovarian cancer. Hepatocyte growth factor (HGF) is important in ovarian cancer cell migration and invasion. This study assessed the effects of YYB-101, a humanized monoclonal anti-HGF antibody, on the growth and metastasis of ovarian cancer cells. YYB-101 suppressed the phosphorylation of the HGF receptor c-MET and inhibited the migration and invasion of SKOV3 and A2780 ovarian cancer cells. Moreover, the combination of YYB-101 and paclitaxel synergistically inhibited tumor growth in an in vivo ovarian cancer mouse xenograft model and significantly increased the overall survival (OS) rate compared with either paclitaxel or YYB-101 alone. Taken together, these findings suggest that YYB-101 has therapeutic potential in ovarian cancer when combined with conventional chemotherapy agents.

引用

页数：10

共 50 条

[1] YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation
Kim, Hyun Jung
Heo, Kyun
ANTICANCER RESEARCH, 2021, 41 (02) : 671 - 678
[2] Anti-hepatocyte growth factor antibody inhibits hepatocyte proliferation during liver regeneration
Burr, AW
Toole, K
Chapman, C
Hines, JE
Burt, AD
JOURNAL OF PATHOLOGY, 1998, 185 (03): : 298 - 302
[3] A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts
Yu, Yanlan
Chen, Yicheng
Ding, Guoqing
Wang, Mingchao
Wu, Haiyang
Xu, Liwei
Rui, Xuefang
Zhang, Zhigen
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (01) : 154 - 160
[4] First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim, Seung Tae
Hong, Jung Yong
Park, Se Hoon
Park, Joon Oh
Park, Young Whan
Park, Neunggyu
Lee, Hukeun
Hong, Sung Hee
Lee, Song-Jae
Song, Seong-Won
Kim, Kyung
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Nam, Hyun
Lee, Jeong-Won
Park, Keunchil
Kim, Kyoung-Mee
Lee, Jeeyun
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[5] Inhibition of Tumor Growth in a Mouse Xenograft Model by the Humanized Anti-HGF Monoclonal Antibody YYB-101 Produced in a Large-Scale CHO Cell Culture
Song, Seong-Won
Lee, Song-Jae
Kim, Chang-Young
Song, Jae-Kyung
Jung, Eui-Jung
Choi, Yong Bock
Min, Sung-Won
Oh, Jong-Won
JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2013, 23 (09) : 1327 - 1338
[6] First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients
Lee, Jeeyun
Kim, Seung
Lee, Sujin
Park, Se Hoon
Park, Joon Oh
Lee, Jeong-Won
Kim, Kyoung Mee
Lee, Hukeun
Hong, Sung
Kim, Jung Yong
Lee, Song-Jae
Song, Seong-Won
Kim, Jung Ju
Park, Young Suk
Lim, Ho Yeong
Kang, Won Ki
Nam, Do-Hyun
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
Kim, KJ
Wang, LH
Su, YC
Gillespie, GY
Salhotra, A
Lal, B
Laterra, J
CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1292 - 1298
[8] SERUM ALBUMIN AS A POTENTIAL PHARMACODYNAMIC BIOMARKER IN PATIENTS TREATED WITH THE ANTI-HEPATOCYTE GROWTH FACTOR MONOCLONAL ANTIBODY FICLATUZUMAB
Su, Wu-Chou
Han, May
Komarnitsky, Philip
Credi, Marc
Mckee, Krista
Strahs, Andrew
Patnaik, Amita
Ramanathan, Ramesh K.
Tan, Eng-Huat
Park, Keunchil
Geater, Sarayut Lucien
Mok, Tony Shu Kam
Elez, Maria-Elena
Tabernero, Josep
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1188 - S1188
[9] Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer
Hori, Akira
Kitahara, Osamu
Ito, Yuki
Nishizawa, Satoru
Misumi, Yuko
Inaoka, Tetsuya
CANCER RESEARCH, 2009, 69
[10] Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab
Kumar, Dhruv
Kandl, Christopher
Hamilton, Chase D'Arcy
Shnayder, Yelizaveta
Tsue, Terance Ted
Kakarala, Kiran
Ledgerwood, Levi
Sun, Xiuzhi Susan
Huang, Hongzhou
Girod, Douglas
Thomas, Sufi Mary
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2015, 141 (12) : 1133 - 1139

← 1 2 3 4 5 →